Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia†
Cristina Papayannidis
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Search for more papers by this authorEnrico Derenzini
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Search for more papers by this authorIlaria Iacobucci
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Search for more papers by this authorAntonio Curti
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Search for more papers by this authorStefania Paolini
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Search for more papers by this authorDaniela Cilloni
Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
Search for more papers by this authorMichele Baccarani
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Search for more papers by this authorCorresponding Author
Giovanni Martinelli
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Institute of Hematology “L. & A. Serà gnoli,” University of Bologna, ItalySearch for more papers by this authorCristina Papayannidis
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Search for more papers by this authorEnrico Derenzini
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Search for more papers by this authorIlaria Iacobucci
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Search for more papers by this authorAntonio Curti
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Search for more papers by this authorStefania Paolini
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Search for more papers by this authorDaniela Cilloni
Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
Search for more papers by this authorMichele Baccarani
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Search for more papers by this authorCorresponding Author
Giovanni Martinelli
Department of Hematology and Medical Oncology, Institute “L. and A. Serà gnoli,” University of Bologna, Italy
Institute of Hematology “L. & A. Serà gnoli,” University of Bologna, ItalySearch for more papers by this authorConflict of interest: Nothing to report.
References
- 1 Xie KC,Plunkett W. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DANN synthesis after treatment of human lymphoblastoid cells with 2-chloro-(2-deoxy-fluoro-β-D-arabinofuranosyl) adenine. Cancer Res 1996; 56: 3030–3037.
- 2 Jeha S,Gaynon PS,Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukaemia. J Clin Oncol 2006; 24: 1917–1923.
- 3 Burnett AK,Russell N,Kell JW, et al. A phase II evaluation of single agent clofarabine as first line treatment for older patients with AML who are not considered fit for intensive chemotherapy. Blood 2004; 104( suppl 1): 248a. Abstract 869.
- 4 Faderl S,Gandhi V,O'Brien S, et al. Results of a phase I-II study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 2005; 105: 940–947.
- 5 Karp JE,Ricklis RM,Balakrishnan K, et al. A phase I clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 2007; 110: 1762–1769.
- 6 Chang JE,Medlin SC,Kahl BS, et al. Augmented and standard Berlin- Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. 2008; 49: 2298–2307.
- 7
Preti HA,Huh YO,O'Brien SM, et al.
Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis.
Cancer
1995;
76:
1564–1570.
10.1002/1097-0142(19951101)76:9<1564::AID-CNCR2820760911>3.0.CO;2-1 CAS PubMed Web of Science® Google Scholar
- 8 Vitale A,Guarini A,Ariola C, et al. Absence of prognostic impact of CD13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Hematologica 2007; 92: 342–348.
- 9 Lucio P,Gaipa G,van Lochem EG, et al. BIOMED-I concerted action report: Flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted action investigation of minimal residual disease in acute leukemia: International standardization and clinical evaluation. Leukemia. 2001; 15: 1185–1192.
- 10 Linenberger ML,Hong T,Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98: 988–994.
Citing Literature
